Looking forward to EHA 2024: key clinical trials to look out for in the myeloma space
EHA2024: welcome from Antonio Almeida, EHA President
EHA 2024 | DREAMM 7 study
Clinical Clips in Advanced Newly Diagnosed Multiple Myeloma: Updates from EHA 2024
Deepthi Samaga Paththaren Eha Discussion - (2024-09-04)
Top Myeloma Research Presented at ASCO & EHA 2024
EHA 2024 | The DREAMM-8 study
ASCO/EHA 2024 Myeloma Highlights- IMROZ, DREAMM-7, DREAMM-8 | Joshua Richter, MD | EHA 2024
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL
What’s New In Follicular Lymphoma: Updates from ASCO 2024 & the EHA Hybrid Congress
Paththaren Eha - (2024-09-12)
MPE Webinar | EHA 2024 myeloma highlights
Deepthi Samaga Paththaren Eha - (2024-09-16)
Highlights from EHA 2024 - Updates on the Treatment of CLL
ASCO/EHA 2024 Myeloma Highlights | Ajai Chari, MD | EHA 2024
CML Highlights of EHA 2024 - Clinical overview
Updates in CLL from EHA 2024: combinations of BTK and BCL2 inhibitors, BTK degraders, and more
Akatakpa Eha-Alumona. Uzo 2024
ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni
EHA 2024 - Updates on CLL with Dr. Banerji, Dr. Assouline, and Dr. Hillis